Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis—a prospective cohort study

Alexandra Cîrciumaru,Yogan Kisten,Monika Hansson,Linda Mathsson-Alm,Vijay Joshua,Heidi Wähämaa,Malena Loberg Haarhaus,Joakim Lindqvist,Leonid Padyukov,Sergiu-Bogdan Catrina,Guozhong Fei,Nancy Vivar,Hamed Rezaei,Erik af Klint,Aleksandra Antovic,Bence Réthi,Anca I Catrina,Aase Hensvold

DOI: https://doi.org/10.1093/rheumatology/keae146

2024-03-08

Rheumatology

Abstract:Abstract Objective Individuals positive for anti-cyclic-peptide-antibodies (anti-CCP) and musculoskeletal complaints (MSK-C) are at risk for developing rheumatoid arthritis (RA). In this study we aimed to investigate factors involved in arthritis progression. Methods Anti-CCP2-positive individuals with MSK-C referred to a rheumatologist were recruited. Individuals lacked arthritis at clinical and ultrasound examination and were followed for ≥3 years or until clinical arthritis diagnosis. Blood samples from inclusion were analysed for nine ACPA reactivities (citrullinated α-1-enolase, fibrinogen, filaggrin, histone, vimentin and tenascin peptides); 92 inflammation-associated proteins; and HLA-shared epitope alleles. Cox regression was applied to the data to identify independent predictors in a model. Results Two hundred and sixty-seven individuals were included with median follow-up of 49 months (interquartile range [IQR]: 22–60); 101 (38%) developed arthritis after a median of 14 months (IQR: 6–27). The analysis identified that presence of at least one ACPA reactivity (hazard ratio [HR] 8.0; 95% CI: 2.9, 22), ultrasound-detected tenosynovitis (HR 3.4; 95% CI: 2.0, 6.0), IL-6 levels (HR 1.5; 95% CI: 1.2, 1.8) and IL-15 receptor α (IL-15Rα) levels (HR 0.6; 95% CI: 0.4, 0.9) are significant independent predictors for arthritis progression in a prediction model (Harrell’s C 0.76 [s.e. 0.02], AUC 0.82 [95% CI: 0.76, 0.89], cross-validated AUC 0.70 [95% CI: 0.56, 0.85]). Conclusion We propose a high RA risk phase characterized by presence of ACPA reactivity, tenosynovitis, IL-6 and IL-15Rα and suggest that these factors need to be further investigated for their biological effects and clinical values, to identify individuals at particular low risk and high risk for arthritis progression.

rheumatology

What problem does this paper attempt to address?

The aim of this paper is to identify the risk factors that lead anti-cyclic citrullinated peptide antibody (anti-CCP) positive individuals to develop rheumatoid arthritis (RA). The study subjects were patients referred from primary care institutions, suspected of having rheumatoid arthritis due to musculoskeletal symptoms (MSK-C), but without clinical and ultrasound evidence of joint inflammation. The study employed a prospective cohort design, recruiting 267 participants from the Karolinska Risk-RA cohort, and followed them for at least 3 years or until arthritis was diagnosed.

Main findings include:
- Among individuals who progressed to arthritis, there was an increase in ACPA reactivity to certain protein-derived citrullinated peptides (96%), compared to only 62% in those who did not progress to arthritis.
- The presence of at least one ACPA reactivity is a strong predictor of arthritis development.
- Proteomics screening showed differences in inflammation-related proteins between the risk RA cohort and healthy controls, with slightly higher serum IL-6 levels and lower IL-15Ra levels in the progressor group.
- Individuals with tenosynovitis detected by ultrasound at baseline were almost destined to develop arthritis (89%).

In summary, the study proposes a high-risk RA stage characterized by the presence of ACPA reactivity, tenosynovitis, elevated IL-6 levels, and reduced IL-15Ra levels. These factors require further investigation for their biological effects and clinical value to identify individuals at particularly low and high risk of developing arthritis.